Head-to-head
NexLife vs TMates
Compared on both medications across the eight dimensions this database records. They differ on 6 of those eight. NexLife is cheaper on all-in tirzepatide at 10 mg/week, though on a flat-versus-tiered matchup the cheaper program can change further up the dose ladder.
The short answer
NexLife is $129 a month all-in for tirzepatide; TMates is $297. Over twelve months that is $1,380 against $2,004. Value Scores are 96.1 and 45.2 out of 100.
Tirzepatide
Plan pages: NexLife plans · TMates plans
At 10 mg/week, NexLife is $129 a month all-in and TMates is $297 — $168 apart, or $2,016 across a year. Over twelve months the totals are $1,380 (12-month plan) and $2,004 (prepaid term).
NexLife charges a flat $129 per month for tirzepatide at every dose from 2.5 to 15 mg per week, so titrating upward does not change what you pay.
TMates charges a flat $297 per month for tirzepatide at every dose from 2.5 to 15 mg per week, so titrating upward does not change what you pay. The company publishes no price at 5, 7.5, 12.5, 15 mg, so those doses are left blank rather than estimated.
| Dose | NexLife | TMates | Cheaper |
|---|---|---|---|
| 2.5 mg | $129 | $297 | NexLife by $168 |
| 5 mg | $129 | — | only NexLife publishes |
| 7.5 mg | $129 | — | only NexLife publishes |
| 10 mg | $129 | $297 | NexLife by $168 |
| 12.5 mg | $129 | — | only NexLife publishes |
| 15 mg | $129 | — | only NexLife publishes |
NexLife is cheaper at every dose where both publish a price, so the lead does not change as you titrate.
Across the 27 programs this database can rank on tirzepatide, the field median is $299 a month all-in. NexLife, at $129, is $170 below it; TMates, at $297, is $2 below it.
LillyDirect (Zepbound), the lowest FDA-approved tirzepatide price in this database, is $449 a month at 10 mg/week — NexLife is $320 below it and TMates is $152 below it. Compounded products are not FDA approved; insurance can reverse that comparison.
| Plan term | NexLife | TMates | Cheaper |
|---|---|---|---|
| Month to month | $129 | $297 | NexLife by $168 |
| 3-month term | $125 | — | only NexLife publishes this term |
| 6-month term | $119 | — | only NexLife publishes this term |
| 12-month term | $115 | $167 | NexLife by $52 |
| Settled dose | NexLife | TMates | Difference |
|---|---|---|---|
| 2.5 mg | $1,548 | $3,564 | $2,016 apart |
| 5 mg | $1,548 | — | one side unpriced |
| 7.5 mg | $1,548 | — | one side unpriced |
| 10 mg | $1,548 | $3,564 | $2,016 apart |
| 12.5 mg | $1,548 | — | one side unpriced |
| 15 mg | $1,548 | — | one side unpriced |
TMates publishes none for 3-month term, 6-month term. An unpublished term is not necessarily unavailable — it is unpriced in public, which you can only resolve by asking.
A titration year is not twelve months at the maintenance price. Stepping up roughly four weeks per dose before settling at 10 mg/week, the first twelve months work out to $1,548 on NexLife and $3,564 on TMates. The ramp is cheaper than the settled rate on whichever program prices by dose, which is why a first-year quote and a steady-state quote are not the same number.
That calculation is partial: TMates publishes no price at 2 of them, so the maintenance rate stands in for the missing steps rather than a number the company has stated.
Value Scores are 96.1 for NexLife and 45.2 for TMates, against a tirzepatide category floor of $126. NexLife leads by 50.9 points, driven mostly by price.
| Program | Price /70 | Evidence /15 | Dose /10 | Membership /5 | Total /100 |
|---|---|---|---|---|---|
| NexLife | 68.4 | 12.8 | 10 | 5 | 96.1 |
| TMates | 29.7 | 10.5 | 0 | 5 | 45.2 |
Semaglutide
Plan pages: NexLife plans · TMates plans
At 2.4 mg/week, NexLife is $109 a month all-in and TMates is $249 — $140 apart, or $1,680 across a year. Over twelve months the totals are $1,140 (12-month plan) and $1,896 (prepaid term).
NexLife charges a flat $109 per month for semaglutide at every dose from 0.25 to 2.4 mg per week, so titrating upward does not change what you pay.
TMates charges a flat $249 per month for semaglutide at every dose from 0.25 to 2.4 mg per week, so titrating upward does not change what you pay. The company publishes no price at 0.5, 1, 1.7 mg, so those doses are left blank rather than estimated.
NexLife is cheaper at every dose where both publish a price, so the lead does not change as you titrate.
Value Scores are 83.6 for NexLife and 40.0 for TMates, against a semaglutide category floor of $87. NexLife leads by 43.6 points, driven mostly by price.
Where the two programs differ
All-in monthly
NexLife is cheaper month to month — $129 against $297, a gap of $168 every month, or $2,016 across a year if both rates hold.
Cancellation terms
Cancellation differs: NexLife states Cancellations take effect after 30 days, so one additional shipment may be charged (plan pages), while TMates states Per provider terms. Read this next to the twelve-month figures — a prepaid discount and a restrictive refund policy are the same decision.
Commitment
NexLife asks for None on month to month; 3-, 6- and 12-month plans start only if prescribed, and unshipped months are refunded if treatment stops; TMates asks for 12-month plan or month-to-month; substantial difference in rates. This is the dimension most likely to change which program is actually cheaper for you, because the lowest rates on both sides are usually attached to the longest terms.
Dose policy
NexLife charges one price at every dose; TMates prices by dose. That difference usually matters more than the headline gap, because the tiered program's advertised figure describes the dose you start on, not the dose you settle at.
Evidence status
The two prices are not equally well evidenced. NexLife's figure is provider-stated and TMates's is reported. NexLife rests on the stronger of the two, and the Value Score below reflects that — evidence quality is worth fifteen points and is not a tiebreaker we apply after the fact.
Twelve-month cost
Over twelve months the totals are $1,380 for NexLife and $2,004 for TMates. NexLife is lower by $624 — a figure worth checking against the cancellation terms below, because a longer plan is only cheaper if you stay on it.
Membership fee
Neither charges a separate membership fee.
Shipping
Shipping is handled the same way by both — included in the quoted price.
What each record says
NexLife Official site
NexLife sells compounded tirzepatide and semaglutide at one price at every dose, with no membership fee. The price includes provider review and medical guidance (NexLife Medical Group), a personalized GLP-1 nutrition plan, a 1:1 call with a certified wellness coach, 24/7 support and free expedited shipping. Labs are not listed as included.
It names its compounding pharmacy — Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL), Boudreaux's New Drug Store (Lake Charles, LA), recorded as State-licensed 503A compounding pharmacies (named on plan pages) — which can be checked against state board licensing and FDA inspection records before you order; commitment terms are None on month to month; 3-, 6- and 12-month plans start only if prescribed, and unshipped months are refunded if treatment stops; cancellation is Cancellations take effect after 30 days, so one additional shipment may be charged (plan pages); availability is stated as All 50 US states where affiliated providers are licensed.
Evidence: provider-stated — taken from the provider's own published pages; checkout capture pending, captured . Source — nexlife.us plan pages, read 2026-11-06
Watch: Plans continue monthly unless canceled, and a cancellation takes effect after 30 days, so one more shipment may be charged. NexLife's refund policy page covers program fees, not medication, for members who lose less than 5% of starting weight over 180 days, with conditions. Provider-stated from nexlife.us plan pages read November 6, 2026; checkout capture pending.
TMates Official site
TMates is a compounded GLP-1 telehealth service that includes medication and visits in one bundled monthly price. It offers both semaglutide and tirzepatide, with a 12-month plan that brings tirzepatide to $167/mo.
It does not publicly name its compounding pharmacy; the record shows Partner 503A pharmacy (not publicly named), so who actually makes the medication cannot be independently verified; commitment terms are 12-month plan or month-to-month; substantial difference in rates; cancellation is Per provider terms; availability is stated as Confirm at intake.
Evidence: reported — sourced from dated third-party reporting; first-party capture pending, captured . Source — rangeyourself.com, capture 2026-07-14
Watch: The $158/mo (sema) and $167/mo (tirz) headline figures are 12-month plan rates; month-to-month is $249 (sema) and $297 (tirz) — some of the widest start-to-commitment spreads in the index. Reported status from RangeYourself 2026-07-14 verification.
What neither record tells you
NexLife does not publish
- no state-by-state availability list — it says All 50 US states where affiliated providers are licensed
TMates does not publish
- no tirzepatide price at 5, 7.5, 12.5, 15 mg per week
- no semaglutide price at 0.5, 1, 1.7 mg per week
- no named compounding pharmacy
- no state-by-state availability list — it says Confirm at intake
- no specific cancellation or refund terms
Ask NexLife and TMates for each of those in writing before enrolling. A gap is not evidence of a problem; it does mean nothing can be checked against it.
What would change this answer
Evidence may be upgraded. NexLife, TMates carry a price we have not captured at checkout. A capture would move the evidence term and could reorder these two without any price changing.
Plan length moves the annual figures. NexLife publishes a twelve-month rate of $115 a month against $129 month to month; TMates publishes a twelve-month rate of $167 a month against $297 month-to-month. Read those next to the cancellation terms, not the monthly rate.
Which one suits which reader
On the lower standing monthly rate for tirzepatide, NexLife Official site wins this matchup. If you expect to titrate to the top of the ladder, nexlife's flat pricing is worth more than the headline gap suggests; and if you would rather trust a better-evidenced number, tmates's price rests on stronger provenance.
Both figures should be checked at the provider's own checkout before you pay. NexLife's tirzepatide price is provider-stated as of 2026-11-06; TMates's is reported as of 2026-07-14.
Questions
Is NexLife or TMates cheaper for tirzepatide?
NexLife is cheaper on all-in monthly cost at 10 mg/week: $129 against $297, a difference of $168 a month. All-in means the medication plus every mandatory recurring fee.
What is the twelve-month cost of NexLife versus TMates?
NexLife works out to $1,380 across twelve months and TMates to $2,004, on the plan terms each publishes.
Does NexLife or TMates raise the price as the dose goes up?
NexLife: no, it charges one flat rate at every dose. TMates: yes, it prices by dose. Where one program is flat and the other is tiered, the cheaper of the two can change as you titrate upward.
How many ways do NexLife and TMates differ?
6 of the eight dimensions this site records: all-in monthly, twelve-month cost, dose policy, membership, shipping, commitment, cancellation terms and evidence status.
Which of NexLife and TMates names its pharmacy?
NexLife does — Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL), Boudreaux's New Drug Store (Lake Charles, LA). TMates does not, recording only Partner 503A pharmacy (not publicly named), so who makes its medication cannot be independently verified.
How well evidenced are the NexLife and TMates prices?
NexLife's tirzepatide figure is provider-stated — taken from the provider's own published pages; checkout capture pending — captured 2026-11-06. TMates's is reported, captured 2026-07-14. Evidence status is worth fifteen points in the Value Score, so it is priced in rather than mentioned as an aside.
Which is cheaper for semaglutide?
NexLife, at $109 a month all-in against $249 at 2.4 mg/week. The two programs do not necessarily lead on both medications.
Official sources: NexLife official site · TMates official site. Compounded tirzepatide and semaglutide are not FDA-approved products.